Allogene Therapeutics (ALLO) Stock Forecast & Price Target

$2.88

0.00 (0.00%)

(As of 09/18/2024 ET)

Allogene Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy
Based on 11 Analyst Ratings

Based on 11 Wall Street analysts who have issued ratings for Allogene Therapeutics in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 11 analysts, 3 have given a hold rating, and 8 have given a buy rating for ALLO.

Consensus Price Target

$9.96
245.68% Upside

High Forecast	$14.00
Average Forecast	$9.96
Low Forecast	$4.60

According to the 11 analysts' twelve-month price targets for Allogene Therapeutics, the average price target is $9.96. The highest price target for ALLO is $14.00, while the lowest price target for ALLO is $4.60. The average price target represents a forecasted upside of 245.68% from the current price of $2.88.

Type	Current Forecast 9/20/23 to 9/19/24	1 Month Ago 8/21/23 to 8/20/24	3 Months Ago 6/22/23 to 6/21/24	1 Year Ago 9/20/22 to 9/20/23
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	8 Buy rating(s)	8 Buy rating(s)	7 Buy rating(s)	9 Buy rating(s)
Hold	3 Hold rating(s)	3 Hold rating(s)	3 Hold rating(s)	2 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$9.96	$9.96	$9.95	$16.35
Forecasted Upside	245.68% Upside	234.95% Upside	205.68% Upside	162.54% Upside

Man who Predicted Trump 2016 Win: “Prepare for Election Meltdown” (Ad)

Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.

Click here to see it because it’s a SHOCKER…

ALLO Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ALLO Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Allogene Therapeutics Stock vs. The Competition

Type	Allogene Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	2.73	2.77	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	245.68% Upside	1,010.31% Upside	7.94% Upside
News Sentiment Rating	Positive News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
8/15/2024	HC Wainwright 2 of 5 stars		Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $9.00	+300.00%
8/9/2024	Citigroup 3 of 5 stars		Boost Target	Buy ➝ Buy	$7.00 ➝ $8.00	+244.83%
8/9/2024	Truist Financial 1 of 5 stars		Reiterated Rating	Buy ➝ Buy	$17.00 ➝ $14.00	+493.22%
8/8/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$13.00 ➝ $11.00	+345.34%
8/8/2024	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$35.00 ➝ $14.00	+466.80%
5/31/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Overweight	$11.00	+347.15%
Man who Predicted Trump 2016 Win: “Prepare for Election Meltdown” (Ad) Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now. Click here to see it because it’s a SHOCKER…
5/14/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Hold ➝ Hold	$4.40 ➝ $4.60	+58.62%
3/15/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$10.00	+130.41%
2/27/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$9.00 ➝ $8.00	+54.44%
1/5/2024	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Neutral
1/5/2024	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Market Perform
4/17/2023	EF Hutton Acquisition Co. I Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy	$15.00	+209.92%
3/22/2023	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Corwin Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
3/21/2023	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Market Perform	$6.00	+11.73%
3/1/2023	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy	$35.00 ➝ $31.00	+388.19%
3/1/2023	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$18.00 ➝ $15.00	+136.22%
1/6/2023	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Outperform	$12.00	+106.54%
12/12/2022	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Underperform	$24.00 ➝ $9.00	+2.74%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 05:24 AM ET.

ALLO Forecast - Frequently Asked Questions

What is Allogene Therapeutics' forecast for 2024?: According to the research reports of 11 Wall Street equities research analysts, the average twelve-month stock price forecast for Allogene Therapeutics is $9.96, with a high forecast of $14.00 and a low forecast of $4.60.
Should I buy or sell Allogene Therapeutics stock right now?: 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allogene Therapeutics in the last twelve months. There are currently 3 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ALLO shares.
Does Allogene Therapeutics's stock price have much upside?: According to analysts, Allogene Therapeutics's stock has a predicted upside of 234.95% based on their 12-month stock forecasts.
What analysts cover Allogene Therapeutics?: Allogene Therapeutics has been rated by research analysts at Canaccord Genuity Group, Citigroup, HC Wainwright, Oppenheimer, and Truist Financial in the past 90 days.
Do Wall Street analysts like Allogene Therapeutics more than its competitors?: Analysts like Allogene Therapeutics less than other "medical" companies. The consensus rating score for Allogene Therapeutics is 2.73 while the average consensus rating score for "medical" companies is 2.77. Learn more on how ALLO compares to other companies.